Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The payment automation software producer received another $128m for a Mastercard-backed round that lifted its overall funding past $1.1bn.

GV, AbbVie Ventures and NS Investment have contributed to a series B round for the oncology drug developer, which has now raised a total of $103m.

The HLB-led group owns nearly half of vaccine product developer Immunomic Therapeutics following a $61.3m commitment this year.

Partners Innovation Fund joined Syncona to provide $20m for the neurological disease drug developer's series A round, which is sized at up to $77m.

BP Ventures led a series B equity and debt round for the charger provider that also featured another corporate investor, ABB Technology Ventures.

The high-performance metal powder developer secured $21.1m in a round led by The Heritage Group's investment subsidiary, which provided $7m.

Red Star Macalline was among the participants in a $14.1m round for the semiconductor production equipment maker that will fund hiring and product development.

CAS Shanghai Institutes for Biological Sciences spinout Aptbio secured funding to enhance its mass spectrometry drug screening business.

The Parkinson's disease therapy developer completed a series A round featuring QB3-aligned Mission Bay Capital.